Skip to main content
. 2012 Aug 23;107(7):1075–1082. doi: 10.1038/bjc.2012.346

Figure 2.

Figure 2

Overall survival (OS) after brain metastasis (BM) by anti-HER2 treatment received after diagnosis of brain metastasis (BM). (A) Anti-HER2 treatment vs no anti-HER2 treatment. Median OS after BM for all patients was 10.9 months (95% CI 9.0–11.9). (B) Both agents vs lapatinib only vs trastuzumab only vs no anti-HER2 treatment. Median OS after BM for all patients was 10.9 months (95% CI 9.0–11.9). *Trastuzumab and lapatinib given sequentially or concomitantly.